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ORIGINAL ARTICLE
Interplay of host genetics and gut microbiota
underlying the onset and clinical presentation
of inﬂammatory bowel disease
Floris Imhann,1,2 Arnau Vich Vila,1,2 Marc Jan Bonder,2 Jingyuan Fu,3 Dirk Gevers,4
Marijn C Visschedijk,1,2 Lieke M Spekhorst,1,2 Rudi Alberts,1,2 Lude Franke,2
Hendrik M van Dullemen,1 Rinze W F Ter Steege,1 Curtis Huttenhower,4,6
Gerard Dijkstra,1 Ramnik J Xavier,4,5 Eleonora A M Festen,1,2 Cisca Wijmenga,2
Alexandra Zhernakova,2 Rinse K Weersma1
ABSTRACT
Objective Patients with IBD display substantial
heterogeneity in clinical characteristics. We hypothesise
that individual differences in the complex interaction of
the host genome and the gut microbiota can explain the
onset and the heterogeneous presentation of IBD.
Therefore, we performed a case–control analysis of the
gut microbiota, the host genome and the clinical
phenotypes of IBD.
Design Stool samples, peripheral blood and extensive
phenotype data were collected from 313 patients with
IBD and 582 truly healthy controls, selected from a
population cohort. The gut microbiota composition was
assessed by tag-sequencing the 16S rRNA gene. All
participants were genotyped. We composed genetic risk
scores from 11 functional genetic variants proven to be
associated with IBD in genes that are directly involved in
the bacterial handling in the gut: NOD2, CARD9,
ATG16L1, IRGM and FUT2.
Results Strikingly, we observed signiﬁcant alterations
of the gut microbiota of healthy individuals with a high
genetic risk for IBD: the IBD genetic risk score was
signiﬁcantly associated with a decrease in the genus
Roseburia in healthy controls (false discovery rate
0.017). Moreover, disease location was a major
determinant of the gut microbiota: the gut microbiota of
patients with colonic Crohn’s disease (CD) is different
from that of patients with ileal CD, with a decrease in
alpha diversity associated to ileal disease
(p=3.28×10−13).
Conclusions We show for the ﬁrst time that genetic
risk variants associated with IBD inﬂuence the gut
microbiota in healthy individuals. Roseburia spp are
acetate-to-butyrate converters, and a decrease has
already been observed in patients with IBD.
BACKGROUND AND AIMS
IBD, comprising Crohn’s disease (CD) and ulcera-
tive colitis (UC), is a chronic inﬂammatory disorder
of the GI tract. In CD, inﬂammation can occur
throughout the GI tract, whereas in UC, inﬂamma-
tion is conﬁned to the mucosal layer of the colon.
The clinical characteristics of IBD vary greatly
between individuals with respect to disease loca-
tion, disease activity and disease behaviour. The
origin of this heterogeneous clinical presentation
remains poorly understood.1 2
The pathogenesis of IBD consists of an exagger-
ated immune response in a genetically susceptible
Signiﬁcance of this study
What is already known on this subject?
▸ The gut microbiota plays a key role in the
pathogenesis of IBD.
▸ Known and presumed epidemiological risk
factors for developing IBD such as mode of
birth, breast feeding, smoking, hygiene,
infections, antibiotics, diet and stress are all
known to cause gut microbial perturbations.
▸ The large heterogeneity between patients with
IBD is likely to result from individual differences
in the complex interaction between the host
genome and the gut microbiota.
▸ Discovering gene–microbiota interactions is
difﬁcult due to the large number of genomic
markers as well as microbial taxa, requiring
stringent multiple testing corrections.
What are the new ﬁndings?
▸ Gut microbial changes could precede the onset
of IBD. A high IBD genetic risk score is
associated with a decrease in the genus
Roseburia in the gut microbiota of healthy
controls without gut complaints.
▸ Disease localisation is a major determinant of
the IBD-associated gut microbiota composition.
▸ The use of a large well-phenotyped healthy
control cohort next to an IBD cohort leads to
an improved list of IBD-associated gut microbial
differences.
How might it impact on clinical practice in
the foreseeable future?
▸ Better understanding of gene–microbiota
interactions and proinﬂammatory gut microbial
changes that precede the onset of IBD can lead
to new IBD therapeutics, and perhaps even
microbial prevention strategies.
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host to the luminal microbial content of the gut. Driven by
rapidly evolving genotyping and next-generation sequencing
technologies, tremendous progress has been made in decipher-
ing the host genomic landscape of IBD.3 4 Systems biology
approaches to genomic and biological data clearly show the
importance of the interaction between the host genome and the
microbial exposure in the gut.5 Moreover, known and presumed
epidemiological risk factors for developing IBD such as mode of
birth (vaginal vs caesarean section), breast feeding, smoking,
hygiene, infections, antibiotics, diet, stress and sleep pattern are
all known to cause microbial perturbations, suggesting a key
role for the gut microbiota in the pathogenesis of IBD.6–9
Previous studies have shown a reduced biodiversity in the gut
microbial composition of patients with IBD, characterised by a
reduction of known beneﬁcial bacteria, such as Faecalibacterium
prausnitzii, Roseburia intestinalis and other butyrate producers,
and an increase of pathogens or pathobionts, for example,
adherent-invasive Escherichia coli and Shigella species of the
Enterobacteriaceae family. However, these studies used a rela-
tively small number of controls, who were usually selected from
the patient population of the gastroenterology department after
excluding those with IBD.10 Because recent gut microbiome
research has shown signiﬁcant effects of stool consistency and
functional complaints on the gut microbiota,11–13 previous
results could have been inﬂuenced by their method of selection
of controls.
While the main composition of the gut microbiota in CD has
been studied extensively, the composition of the gut microbiota
in patients with UC has received less attention.10 14 15
Furthermore, the relationship between the gut microbiota and
the clinical characteristics of IBD, including disease activity,
disease duration and disease behaviour has only been studied in
an exploratory manner.
Recent studies have begun to unravel the complex interaction
of host genetics and the gut microbiota. These links between
speciﬁc genetic variants and the abundance of speciﬁc bacteria
are called microbiota quantitative trait loci (microbiotaQTLs).
Twin studies show that the abundances of bacterial families
Ruminococcaceae and Lachnospiraceae containing butyrate pro-
ducers and acetate-to-butyrate converters are, to a certain
degree, heritable.16–18 Animal studies in mice speciﬁcally
designed to discover microbiotaQTLs show the inﬂuence of
genomic loci on several microbial genera.19 Moreover, gut
microbiota similarities in twins both concordant and discordant
for IBD have been shown in several studies, further suggesting
that host genetics can inﬂuence the gut microbiota.20–22
Furthermore, preliminary data show that speciﬁc variants of the
NOD2 gene are associated with changes in the abundance of
the Enterobacteriaceae family in patients with IBD.23
We hypothesise that the large heterogeneity between patients
with IBD is likely to result from individual differences in the
complex interaction between the host genome and the gut
microbiota. Therefore, improving our knowledge of this inter-
action is crucial for our understanding of the pathogenesis of
IBD.14 So far, very few studies have been able to elucidate this
interaction in an integrated manner. Here, we present a large
single-centre case–control analysis of the luminal gut micro-
biota, the host genetics and clinical phenotypes of both CD and
UC. To ensure optimal data quality, we adopted a rigorously
standardised approach to collect and process fresh frozen faecal
samples of 313 patients with IBD from a single hospital in the
north of the Netherlands and 582 truly healthy controls from
the same geographical area. For all individuals, extensive clinical
data, laboratory and endoscopic ﬁndings were collected. In
addition, host genomic risk variants and risk scores were
obtained in both the patients with IBD and the healthy controls




In total, 357 patients with IBD were recruited from the specia-
lised IBD outpatient clinic at the Department of
Gastroenterology and Hepatology of the University Medical
Center Groningen (UMCG) in Groningen, the Netherlands. All
patients with IBD were diagnosed based on accepted radio-
logical, endoscopic and histopathological evaluation. We
excluded 44 patients with IBD who had a stoma, pouch or
short bowel syndrome from further analyses. Healthy controls
were selected from the 1174 participants of LifeLines DEEP, a
cross-sectional general population cohort in the northern pro-
vinces of the Netherlands.24 Data about medical history, medi-
cation use and gut complaints were meticulously reviewed by a
medical doctor to ensure controls did not have any severe gut
complaints or diseases, and did not use any medication that
could confound our analysis of the gut microbiota. The selec-
tion process is described in detail in the online supplementary
appendix. Pseudonymised data from patients with IBD and
healthy controls were provided to the researchers. This study
was approved by the Institutional Review Board of the UMCG
(IRB number 2008.338). All participants signed an informed
consent form.
Clinical characteristics and medication use of patients with
IBD
Extensive data on clinical characteristics and medication use
were available for all patients with IBD at the time of stool sam-
pling. Pseudonymised data were retrieved from the IBD-speciﬁc
electronic patient records of the IBD Center at the Department
of Gastroenterology and Hepatology of the UMCG. Disease
activity at the time of sampling was determined by standardised
and accepted clinical activity scores: the Harvey–Bradshaw
index (HBI) for patients with CD and the Simple Clinical
Colitis Activity Index (SCCAI) score for patients with UC. C
reactive protein (CRP) and faecal calprotectin measurements
were also available as indicators of disease activity. Disease local-
isation and behaviour were described according to the Montreal
classiﬁcation. Disease duration was determined as date of stool
sampling in the study minus the date of diagnosis. IBD treat-
ment at the time of sampling was scored (mesalazine, steroids,
thiopurines, methotrexate, tumour necrosis factor α (TNF-α)
inhibitors and other biologicals) as well as the use of other med-
ications: proton pump inhibitors (PPIs), antidiarrhoeal medica-
tion (loperamide), bile salts, iron, minerals and vitamins at the
time of sampling, and antibiotics use within the previous 3
months. Extraintestinal manifestations and complications of IBD
were scored in several categories: (1) eye; (2) mouth; (3) skin;
(4) joints; (5) Other (details in online supplementary appendix).
Serological measurements for antineutrophil cytoplasmic anti-
bodies and anti-Saccharomyces cerevisiae antibodies were deter-
mined by immunoﬂuorescence. Information on mode of birth,
breast feeding during infancy and self-reported diets (see online
supplementary appendix) was collected through questionnaires.
The association between a phenotype and the gut microbiota
was only analysed if there were ﬁve or more patients with IBD
with that phenotype. A list of all phenotypes can be found in
the online supplementary appendix.
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Stool sample collection and faecal DNA extraction
Stool samples were collected for 313 cases with IBD and 582
controls. Identical protocols were used to collect and process all
stool samples. All participants were asked to produce a stool
sample at home. These were frozen by the participant within
15 min after stool production in the participant’s home freezer.
A research nurse visited each participant shortly after stool pro-
duction to collect the sample on dry ice for transport to the
UMCG at −80°C. Samples were subsequently stored at −80°C
in the laboratory. All samples remained frozen until DNA isola-
tion for which aliquots were made, and microbial DNA was iso-
lated using the Qiagen AllPrep DNA/RNA Mini Kit cat #
80204 as previously described.10
Host genotyping, variant selection and genetic risk
modelling
Host DNA was available for all patients with IBD and healthy
controls. Host DNAwas isolated from peripheral blood as previ-
ously described.25 Genotyping was performed using the
Immunochip, an Illumina Inﬁnium microarray comprising
196 524 single nucleotide variants (SNPs) and a small number
of insertion/deletion markers, selected based on results from
genome-wide association studies of 12 different immune-
mediated diseases including IBD. Normalised intensities for all
samples were called using the OptiCall clustering program.26
The genotype prediction was improved via stringent calling with
BeagleCall using recommended settings.27 Marker and sample
quality control were performed as previously described.3
Human leucocyte antigen (HLA) imputation was performed
using SNP2HLA. The Type 1 Diabetes Genetics Consortium
genotype data were used as a reference panel for imputation.
The SNP2HLA imputes the classical HLA alleles and amino
acid sequences within the major histocompatibility complex
(MHC) region on chromosome 6.28
To overcome statistical problems inherent to multiple testing
when combining both genome-wide and 16S rRNA microbiota
data, we adopted an approach of analysing a set of selected
SNPs based on (i) their involvement in IBD, (ii) their predicted
functional consequences and (iii) their role in bacterial sensing
and signalling in the gut.23
Eleven known IBD genetic risk variants were selected for our
genome–microbiota interaction analyses. We selected these risk
variants ensuring that the selected IBD risk SNPs (as identiﬁed
in the International IBD Genetics Consortium Immunochip ana-
lysis or targeted resequencing studies) are functional variants
or are in strong linkage disequilibrium with functional variants
that are implicated in the interaction of the host with the gut
microbiota.3 29 We included the following seven genetic variants
in NOD2: rs104895431 (S431L), rs2066844 (R702W),
rs5743277 (R703C), rs104895467 (N852S), rs2066845
(G908R), rs5743293 (fs1007insC) and rs104895444 (V793M).
The variant rs10781499 in CARD9 was selected because Card9
has been shown to mediate intestinal epithelial cell restitution, T
helper 17 responses and control of intestinal bacterial infection
in mice.30 Two variants in FUT2, rs516246 and rs1047781,
were selected because these variants have been shown to inﬂu-
ence colonic mucosa-associated microbiota in CD.31 SNPs
rs11741861 in IRGM and rs12994997 in ATG16L1 were
included because of their role in decreased selective autophagy
that results in altered cytokine signalling and decreased antibac-
terial defence.32 33
In addition to these 11 genetic variants, we also created risk
scores for all 200 known IBD risk variants.3 5 We also analysed
the inﬂuence of the HLA-DRB1*01:03 haplotype on the gut
microbial composition in colonic disease, because this recently
identiﬁed haplotype is associated with both UC and colonic CD
and is suggested to be involved in appropriately controlling the
immune response to colonic microbiota.34
Determining the gut microbial composition
Illumina MiSeq paired-end sequencing was used to determine
the bacterial composition of the stool samples. Forward primer
515F [GTGCCAGCMGCCGCGGTAA] and reverse primer
806R [GGACTACHVGGGTWTCTAAT] of hypervariable
region V4 of the 16S rRNA gene were used. Custom scripts
were used to remove the primer sequences and align the
paired-end reads.10
Operational taxonomic units: operational taxonomic
unit-picking and ﬁltering
The operational taxonomic unit (OTU) selection was performed
using the QIIME reference optimal picking, using Usearch
(V.7.0.1090) to perform the clustering at 97% of similarity.
Greengenes V.13.8 was used as a reference database. In all,
12 556 OTUs were identiﬁed. Samples with less than 10 000
counts were removed. OTUs that were not present in at least
1% of our samples or with a low abundance (<0.01% of the
total counts) were ﬁltered out.
Function prediction
The functional imputation tools PICRUSt and HUMAnN were
used to investigate the functional implications of the gut micro-
biota of patients with IBD. More information about the func-
tion prediction and the software can be found in the online
supplementary appendix.
Statistical analysis
The richness and the β-diversity of the microbiota dataset were
analysed using QIIME.35 The Shannon diversity index and the
number of observed species per sample were used as α-diversity
metrics. β-diversity was calculated using unweighted Unifrac dis-
tances and represented in Principal Coordinate Analyses
(PCoA). The Wilcoxon test and Spearman correlations were
used to identify differences in the Shannon index and the rela-
tions between the principal coordinates. χ2 tests, Fisher’s exact
tests, Spearman correlations and Wilcoxon–Mann-Whitney tests
(WMW tests) were used to determine the differences in the clin-
ical characteristics of patients with IBD. QIIMETOMAASLIN
was used to convert the OTU counts into relative taxonomical
abundance. OTUs representing identical taxonomies were aggre-
gated, and higher taxon levels were added when multiple OTUs
represented that taxon. Due to the limitations of the resolution
on taxonomical classiﬁcation using 16S gene sequencing, we
restricted our analysis to the genus level and above. The initial
12 556 OTUs were classiﬁed into 250 taxonomical levels.
We used MaAsLin to identify differentially abundant taxa and
pathways: (1) between patients with IBD and healthy controls,
(2) between different IBD phenotypes and (3) between indivi-
duals with diverse amounts of IBD genetic risk variants.15
MaAsLin performs boosted additive general linear models
between metadata and microbial abundance data. The default
settings of MaAsLin were used in all analyses. We used the
Q-value package implemented in MaAsLin to correct for mul-
tiple testing. A false discovery rate (FDR) of 0.05 was used as
the cut-off value for signiﬁcance. The effect of the IBD diagno-
sis (CD or UC) on the gut microbiota composition was analysed
by adding the IBD diagnosis versus healthy as a discrete pre-
dictor in the MaAsLin general linear mixed model analysis.
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Unweighted genetic risk scores were calculated for every partici-
pant by summing up the risk alleles of the above-mentioned
SNPs (risk allele=1; IBD protective allele=0).25 Weighted genetic
risk scores were calculated for every participant by summing up
the log-normalised odds of the genetic variants of the same
above-mentioned SNPs. Both risk scores were added as a pre-
dictor to the additive general linear model in MaAsLin. The ana-
lyses of the host genome and the microbiota composition were
performed separately in patients with IBD and healthy controls.
Correction for factors inﬂuencing the gut microbiota
Parameters that potentially inﬂuence the gut microbiota were
identiﬁed by statistical analysis of cohort phenotypes, univariate
MaAsLin analyses and literature search, and subsequently added
as cofactors to the additive linear model. In every analysis, the
parameters age, gender, body mass index, read-depth, PPI use,
antibiotics use and IBD medication (mesalazine, steroids, thio-
purines, methotrexate and TNF-α inhibitors) were added as cov-
ariates. Stool consistency also affects the gut microbiota.
However, since stool consistency, mainly the occurrence of diar-
rhoea, is a key characteristic of increased IBD disease activity,
stool consistency was not used as a covariate in all models.
However, stool consistency was incorporated in the analyses,
since the clinical disease activity scores used––the HBI for CD
and the SCCAI––take the number of liquid stools per day (in
the HBI) and the number of bowel movements during the day
and during the night (in the SCCAI) into account.
RESULTS
The clinical characteristics of patients with IBD and the
selection of healthy controls
The cohort consists of 313 patients with IBD (188 patients with
CD, 107 patients with UC and 18 patients with IBD intermedi-
ate/IBD undetermined (IBDI/IBDU)) and 582 healthy controls
selected from the population cohort LifeLines DEEP (selection
criteria can be found in the online supplementary appendix).24
Patients with CD were younger than healthy controls (41.3 vs
45.9 years; p=1×10−4, WMW test), while patients with UC
were not older than healthy controls (p=0.32, WMW test). At
the time of sampling, 81 patients with IBD (25.8%) had active
disease, deﬁned as an HBI of higher than 4 in patients with CD
or an SCCAI score higher than 2.5 in patients with UC. Of the
patients with IBD, 23.7% had used antibiotics within the last
3 months. PPI use was more frequent in patients with IBD
(24.5%) than in healthy controls (4.7%) (p<0.001, χ2 test).
Extensive information on all clinical characteristics and medica-
tion use is presented in table 1.
Overall composition of the gut microbiota in patients with
IBD and healthy controls
The predominant phyla in both patients with IBD and healthy
controls were Firmicutes (73% in patients with IBD, 75% in
healthy controls), Actinobacteria (9% in patients with IBD, 13%
in healthy controls) and Bacterioidetes (14% in patients with
IBD, 8% in healthy controls). Clostridia was the most abundant
class (64% in patients with IBD, 68% in healthy controls). An
overview of the abundances at all taxonomic levels can be found
in online supplementary table S1.
Alpha diversity
A statistically signiﬁcant decrease in the Shannon index was
observed in patients with IBD compared with healthy controls
as depicted in online supplementary ﬁgure S1 (p=5.61×10−14,
Wilcoxon test) and ﬁgure 1.
Principal coordinate analysis
The differences in gut microbial composition between patients
with IBD and healthy controls were also observed in the PCoA
analysis. Statistically signiﬁcant differences were found in the
ﬁrst three components (PCoA1 p=2.62×10−68, PCoA2
p=0.033, PCoA3 p=1.50×10−10, Wilcoxon test). The gut
microbiota of healthy controls clustered together, while the gut
microbiota of patients with IBD were more heterogeneous, par-
tially overlapping the healthy controls. The shape of the PCoA
plot is mainly explained by the disease location and the
Shannon index (see results below), as depicted in ﬁgure 2A–D.
IBD genetic risk variants are associated to unfavourable gut
microbiota changes in healthy controls
The role of 11 functional genomic variants associated to IBD in
the genes NOD2, CARD9, ATG16L1, IRGM and FUT2 was
investigated. In the unweighted analysis in healthy controls, a
higher number of IBD risk alleles was associated with a decrease
in the abundance of the genus Roseburia of the phylum
Firmicutes (FDR=0.017) as depicted in ﬁgure 3. In patients
with IBD as well as subsets of patients with IBD (patients with
CD, patients with UC, patients with ileal CD, patients with ileo-
colonic CD and patients with colonic CD), neither the single
genetic risk variants, the HLA-DRB1*01:03 haplotype, nor the
weighted or unweighted composite scores of genetic risk alleles
showed any statistically signiﬁcant effect on the gut microbiota
composition. All results of the analyses with the risk scores of
11 SNPs can be found in online supplementary table S2. Risk
scores including all 200 IBD risk SNPs did not show any signiﬁ-
cant relations with the gut microbiota composition.
Dysbiosis in patients with CD and UC: new associations
Crohn’s disease
Compared with healthy controls, 69 taxa were statistically sig-
niﬁcantly altered in patients with CD (genus and above; 28%;
FDR<0.05). These alterations are presented in table 2 and
depicted in the cladogram in online supplementary ﬁgure S2A.
The phyla Bacteroidetes (FDR=1.12×10−14) and
Proteobacteria (FDR=2.71×10−22) were increased, while the
phyla Actinobacteria (FDR=7.15×10−10) and Tenericutes
(FDR=1.90×10−12) were decreased. Within the phylum
Bacteroidetes, the order Bacteroidales was increased
(FDR=1.12×10−14) as well as the genus Parabacteroides within
the family Porphyromonadaceae (FDR=0.0016). Within the
order Clostridiales of the phylum Firmicutes, seven families
were decreased: Mogibacteriaceae, Christensenellaceae,
Clostridiaceae, Dehalobacteriaceae, Peptococcaceae,
Peptostreptococcaceae and Ruminococcaceae (FDR<0.05). The
family Enterobacteriaceae of the phylum Proteobacteria, con-
taining many known gut pathogens, was increased
(FDR=0.0020). The genera Biﬁdobacterium, Ruminococcus and
Faecalibacterium were also decreased in patients with CD
(FDR=2.16×10−6, 4.70×10−5 and 7.82×10−23, respectively).
The changes in relative abundance of the statistically signiﬁ-
cantly altered families are depicted in ﬁgure 4. The complete list
of increased and decreased taxa including direction, coefﬁcient
and FDR values is presented in online supplementary table S3.
Ulcerative colitis
In patients with UC, 38 of the taxa were statistically signiﬁcantly
altered compared with healthy controls (genus and above; 12%;
FDR<0.05). These alterations are presented in table 3 and
depicted in a cladogram in online supplementary ﬁgure S2B.
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Similar to the patients with CD, the abundances of the phyla
Bacteroidetes (FDR=8.87×10−13) and Proteobacteria
(FDR=4.06×10−5) were increased, while the phylum
Firmicutes (FDR=0.0079) was decreased in patients with UC.
Within the phylum Bacteroidetes, the order Bacteroidales
(FDR=8.87×10−13), the family Rikenellaceae (FDR=0.025)
and the genus Bacteroides (FDR=1.72×10−18) were all
increased compared with healthy controls. Lachnobacterium
and Roseburia, genera in the order Clostridiales of the phylum
Firmicutes, were also increased in patients with UC
(FDR=0.023 and FDR=0.00056, respectively). The changes in
relative abundance of the altered families are depicted in ﬁgure 4
(FDR<0.05). The complete list of increased and decreased taxa,
including direction, coefﬁcient and FDR values, is presented in
online supplementary table S3.
Disease location is a major determinant of the gut
microbiota in patients with IBD
The PCoA depicted in ﬁgure 2C shows the difference between the
gut microbiota of patients with colonic disease (colonic CD and
UC combined) and patients with ileal disease (ileal CD and ileoco-
lonic CD combined). There is overlap between healthy controls
and patients with colonic disease, while in concordance with the
α-diversity analysis in ﬁgure 1, the gut microbiota of patients with
ileal disease deviates more from healthy controls. The statistical
analysis of the PCoA supports this result: the ﬁrst component is
related to disease location (PCoA1 r=0.63, p=7.39×10−91,
Spearman correlation), and patients with colonic CD differ from
patients with ileal CD (p=5.42×10−9). The α-diversity analysis
shows similar results: the gut microbiota of patients with IBD with
colonic disease is not statistically signiﬁcantly decreased compared
with healthy controls (Shannon index in patients with UC=6.41
vs Shannon index in healthy controls=6.50, p=0.06; Shannon
index in patients with colonic CD=6.38 vs Shannon index in
healthy controls=6.50, p=0.08, Wilcoxon test). On the contrary,
patients with IBD with ileal disease show a statistically signiﬁcant
decrease in α-diversity (patients with ileal CD vs healthy controls
p=3.28×10−13 and patients with ileocolonic CD vs healthy con-


















































































































































































































































































































































































































































































































































































































































































































































































Figure 1 α-diversity (Shannon index) of the gut microbiota of healthy
controls, patients with UC, patients with colonic Crohn’s disease (CD),
patients with ileocolonic CD and patients with ileal CD. α-diversity is
not decreased in colonic disease (UC and colonic CD) compared with
healthy controls. In contrast, in patients with ileal and ileocolonic CD,
the α-diversity is statistically signiﬁcantly decreased (patients with ileal
CD vs healthy controls p=3.28×10−13 and patients with ileocolonic CD
vs healthy controls p=3.11×10−11, Wilcoxon test).
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Whether the IBD genetic risk was associated with disease
location was also tested. The genetic risk could not explain the
disease location (colonic IBD vs ileal involved IBD; unweighted
genetic risk score using 200 SNPs; Spearman correlation;
r=0.045; p=0.47). The taxonomy analysis of disease location is
presented in the online supplementary appendix.
Effects of IBD disease activity on the gut microbiota
We analysed several read-outs for disease activity at the time of
sample collection: the clinical HBI scores for patients with CD
and SCCAI scores for patients with UC, as well as CRP and
faecal calprotectin level measurements for all patients with IBD.
A higher HBI was associated with an increase of the family
Enterobacteriaceae in patients with CD (FDR=0.036). No sig-
niﬁcant associations were found between the gut microbiota and
the SSCAI in patients with UC. Neither CRP nor faecal calpro-
tectin was statistically signiﬁcantly associated with altered bacter-
ial abundances in the gut. Details of the disease activity analyses
can be found in online supplementary tables S4 and S5.
Effects of IBD disease duration on the gut microbiota
The disease duration in patients with IBD was measured from
the date of diagnosis up to the date of sample collection. A
longer duration of the disease, corrected for age, was associated
with a higher abundance of the phylum Proteobacteria
(FDR=0.045) (see online supplementary table S6).
Analysis of other IBD subphenotypes
Other gut microbial associations with other IBD subphenotypes
including medication, smoking behaviour and extraintestinal
manifestations can be found in the Results section of the online
supplementary appendix.
Pathway prediction and gut microbiota function changes in
patients with IBD
Multiple metabolic pathways including butyrate metabolism,
endotoxin metabolism and antibiotic resistance pathways were
differentially expressed between patients with IBD, UC, CD,
ileal CD, ileocolonic CD and colonic CD as compared with
Figure 2 Principal coordinate analysis (PCoA) of stool samples of 313
patients with IBD and 582 healthy controls. (A) The gut microbiota of
patients with IBD is different from the gut microbiota of healthy
controls, with only partial overlap. (B) The ﬁrst component is related to
the Shannon index. (C and D) There is more overlap between colonic
disease (UC and colonic Crohn’s disease (CD) combined) and healthy
controls than between ileal disease (ileal CD and ileocolonic CD
combined) and healthy controls. The ﬁrst component is related to
disease location (PCoA1 r=0.63, p=7.39×10−91, Spearman correlation)
and patients with colonic CD differ from patients with ileal CD
(p=5.42×10−9).
Figure 3 Increased risk score of 11 IBD-related genetic variants in
gut bacterial handling genes (NOD2, CARD9, IRGM, ATG16L1 and
FUT2) is statistically signiﬁcantly associated to decreased abundance of
Roseburia spp. in healthy controls (false discovery rate=0.017).
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Table 2 Comparison of altered taxa in patients with Crohn’s disease (CD) compared with healthy controls: family level and above




kingdom) Current study* Gevers et al† Morgan et al‡ Willing et al§
f__Methanobacteriaceae Archea (kingdom) Down Not reported Not reported Not reported
p__Actinobacteria Down Down Not reported Up in colonic CD
c__Actinobacteria Actinobacteria Down Down Not reported Up in colonic CD
f__Micrococcaceae Actinobacteria Not reported Up Not reported Not reported
f__Bifidobacteriaceae Actinobacteria Down Down Down, in lower
taxonomic levels
Up in colonic CD
f__Coriobacteriaceae Actinobacteria Down Down Not reported Up in colonic CD
p__Bacteroidetes Up Down Not reported Not reported
o__Bacteroidales Bacteriodetes Up Down Not reported Not reported
f__Porphyromonadaceae Bacteriodetes Up Down Down, in lower
taxonomic levels
Unknown genus in this
family: down in ileal CD
p__Firmicutes Down, in lower taxonomic levels Down Down Up in colonic CD
c__Bacilli Firmicutes Up, in lower taxonomic levels Up Associated to ileal
involvement
Up in ileal CD
f__Aerococcaceae Firmicutes Up Not reported Not reported Not reported
f__Enterococcaceae Firmicutes Up Not reported Not reported Not reported
o__Gemellales Firmicutes Not reported Up Not reported Not reported
f__Gemellaceae Firmicutes Not reported Up Not reported Not reported
f__Streptococcaceae Firmicutes Not reported Up Not reported Not reported
c__Clostridia Firmicutes Down Down Down Down in ileal CD
o__Clostridiales Firmicutes Down Down Down Down in ileal CD
f__Mogibacteriaceae Firmicutes Down Not reported Not reported Not reported
f__Christensenellaceae Firmicutes Down Down Not reported Not reported
f__Clostridiaceae Firmicutes Down Down Not reported Not reported
f__Dehalobacteriaceae Firmicutes Down Not reported Not reported Not reported
f__Lachnospiraceae Firmicutes Up, but genera in lower levels
both going up and down
Down Down, in lower
taxonomic levels
Down, in lower taxonomic levels
f__Peptococcaceae Firmicutes Down Not reported Not reported Down in ileal CD
f__Peptostreptococcaceae Firmicutes Down Not reported Not reported
f__Ruminococcaceae Firmicutes Down Down Down Down in ileal CD
f__Veillonellaceae Firmicutes Not reported Up Up Up in lower taxonomic
levels in ileal CD
f__Erysipelotrichaceae Firmicutes Down Down Associated to ileal
involvement
Not reported
p__Fusobacteria Not reported Not reported Not reported Up in ileal CD
o__Fusobacteriales Fusobacteria Not reported Up Not reported Up in ileal CD
f__Fusobacteriaceae Fusobacteria Not reported Up Not reported Up in ileal CD
p__Proteobacteria Up Up Up Up in ileal CD
c__Betaproteobacteria Proteobacteria Up Up Not reported Not reported
o__Burkholderiales Proteobacteria Up Up Not reported Not reported
f__ Neisseriaceae Proteobacteria Not reported Up Not reported Not reported
c__Gammaproteobacteria Proteobacteria Up Up Up Up in ileal CD
f__Aeromonadaceae Proteobacteria Not reported Not reported Not reported Up in ileal CD
o__Campylobacterales Proteobacteria Not reported Up Not reported Not reported
f__Enterobacteriaceae Proteobacteria Up Up Up Up in ileal CD
f__Pasteurellaceae Proteobacteria Not reported Up Not reported
p__Tenericutes Down Not reported Not reported
c__Mollicutes Tenericutes Down Not reported Not reported Down in ileal CD, up in
colonic CD
f__Anaeroplasmataceae Tenericutes Not reported Not reported Not reported Down in ileal CD,
up in colonic CD
f__Verrucomicrobiaceae Verrucomicrobia Not reported Down Not reported Not reported
k__, kingdom; p__; phylum; c__ , class; o__ , order; f__, family.
*313 patients with IBD including 188 patients with CD; 582 healthy controls; stool only.
†Cell Host Microbe 2014; 447 patients with CD; 221 controls; stool and biopsy.
‡Genome Biology 2012; 204 patients with IBD including 121 patients with CD and 27 controls; stool and biopsy.
§Gastroenterology 2010; 40 twin pairs concordant or discordant for CD/UC (23 CD pairs, 15 UC pairs, 2 healthy pairs).
FDR, false discovery rate.
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healthy controls. These altered Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathways are presented in online
supplementary ﬁgure S3 and table S7. The metabolism of short
chain fatty acids was decreased in patients with IBD, as indi-
cated by the decrease of the propanoate (also known as propi-
onate) metabolism in patients with CD and UC (ko00640; CD:
FDR=2.74×10−11 and UC: FDR=3.59×10−5), the decrease of
the butanoate (also known as butyrate) metabolism in patients
with CD (ko00650; FDR=5.31×10−9) and the decreased fatty
acid metabolism in patients with CD (ko00071;
FDR=4.28×10−18). Lipopolysaccharide or endotoxin biosyn-
thesis was increased in both patients with CD and UC
(ko00540; CD: FDR=4.69×10−7 and UC: FDR=0.027).
β-lactam resistance metabolism was increased in patients with
CD (ko00312; FDR=4.69×10−7). There were no signiﬁcant
pathway increases or decreases related to the clinical disease
activity score, the HBI, for patients with CD (see online
supplementary table S8). More detailed information on the pre-
dicted pathways can be found in the Results section of the
online supplementary appendix.
CONCLUSIONS
By performing this extensive integrated case–control analysis of
the gut microbiota, the host genome and the clinical character-
istics of IBD, we have identiﬁed new gut microbial associations
with IBD and are now able to reﬁne our understanding of the
ﬁndings of previous studies. We found a relation between host
genetic IBD susceptibility variants and the gut microbiota com-
position in healthy individuals and observed the effect of
disease location on the gut microbiota. Moreover, we report
microbial associations with multiple IBD subphenotypes.
Onset of IBD: genetic risk factors for IBD associated with
proinﬂammatory gut microbiota alterations in healthy
individuals
Discovering gene–microbiota interactions is difﬁcult due to the
large number of genomic markers as well as microbial taxa,
requiring stringent multiple testing correction, thus limiting the
possibility of ﬁnding statistically signiﬁcant results. To resolve
this issue, we created risk scores of known functional IBD risk
variants proven to be involved in the bacterial handling in the
gut. This hypothesis-based gene–microbiota approach limits the
number of tests that need to be done and has proven to be
successful.
The gut microbiota interacts with the intestinal epithelium
and the host immune system.18 36–39 Recently, it was hypothe-
sised that the interaction of the immune system with the gut
microbiota goes two ways: ‘good’ gut microbiota can ameliorate
immune responses, but the gut immune system can also ‘farm’
good bacteria in order to maintain immune–microbe homeosta-
sis.36 37 We can show support for this hypothesis: in healthy
individuals, an increased genetic burden in functional variants
in genes involved in bacterial handling (NOD2, IRGM,
ATG16L1, CARD9 and FUT2) is associated with a decrease of
the acetate-to-butyrate converter Roseburia spp.
The species Roseburia intestinales is one of the 20 most abun-
dant species in the gut microbiota.40 Importantly, a decrease in
Roseburia spp. is already associated to the gut microbiota of
patients with IBD.10 15 In an in vitro model, Roseburia spp. spe-
ciﬁcally colonised the mucins, which govern mucosal butyrate
production.41 Butyrate derived from Clostridium clusters IV,
VIII and XIVa to which Roseburia spp. belong has been shown
to induce Treg cells, preventing or ameliorating intestinal inﬂam-
mation.38 39 The abundances within the family
Lachnospiraceae, to which Roseburia spp. belong, are signiﬁ-
cantly more similar in monozygotic twins than in dizygotic
twins.17 Moreover, unaffected siblings of patients with CD
share a decrease in Roseburia spp.22
This ﬁnding in healthy individuals carrying IBD genetic risk
variants has implications for our understanding of the onset of
IBD. We hypothesise that genetic risk factors of the gut immune
system lead to ‘farming’ of a more proinﬂammatory gut micro-
biota and increased susceptibility to IBD. Subsequent unfavour-
able microbial perturbations due to environmental risk factors
could further disturb the immune–microbe homeostasis in the
gut, eventually leading to IBD.
In addition to our genetic risk score based on speciﬁc func-
tions, analyses using genetic risk scores of all 200 known IBD
susceptibility variants, many of whose function is unknown, did
not yield any statistically signiﬁcant results in either patients
with IBD or in healthy controls. We could not detect any gene–
microbiota interactions in patients with IBD, probably due to
the already well-established dysbiosis as a consequence of the
inﬂammation in the gut. Another complication is the
Figure 4 Log2-fold change of
increased and decreased bacterial
families in patients with UC and
Crohn’s disease versus healthy controls
(false discovery rate<0.05).
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interrelatedness of the genotypes and phenotypes in IBD. For
example, NOD2 risk variants are known to be associated with
ileal CD, and we show that ileal CD has a speciﬁc microbial sig-
nature. After correction for treatment, disease activity and
disease location, we could not ﬁnd any statistically signiﬁcant
genome–microbiota relations in patients with IBD.
Dysbiosis in patients with CD and UC: new associations
identiﬁed, previous associations corrected
The dysbiosis of the gut microbiota in patients with IBD is pro-
found: the abundances of 69 taxa in patients with CD and 38
taxa in patients with UC were altered compared with healthy
individuals (FDR<0.05). We compared our results on the
phylum, class, order and family levels with two previous studies
looking into the gut microbiota of patients with IBD.10 15 20
This comparison is presented in tables 2 (patients with CD) and
3 (patients with UC). An important new ﬁnding of our study is
the increase in the phylum Bacteroidetes in both patients with
CD and UC. Increased levels of Bacteroidetes have recently
been discovered in patients with IBS.13 Since the control groups
used in the previous IBD studies also had functional GI com-
plaints (ie, IBS), this would have confounded any comparisons
between Bacteroidetes levels in patients with IBD and controls,
masking any meaningful enrichment in IBD.
The genus Bacteroides within the phylum Bacteroidetes is
increased in our patients with UC. The involvement of
Bacteroides spp in the pathogenesis of IBD has been implied in
animal studies. In NOD2 knockout mice, the exaggerated
inﬂammatory response in the small intestine was dependent on
Bacteroides vulgatus.42 Bacteroides thetaiotaomicron induced
colitis in HLA-B27 transgenic rats.43 Another study looking into
the effects of the vitamin D receptor in mice found increased
levels of Bacteroides spp in colitis and increased levels of
Bacteroides fragilis in colon biopsies of patients with UC.44
Increased abundance of the families Streptococcaceae,
Micrococcaceae and Veillonellaceae, previously associated with
IBD, is now associated to PPI use in our study. PPI use is overre-
presented in patients with IBD.45 Since previous studies did not
correct for PPI use, we assume that alterations in the abun-
dances of these taxa were wrongly assigned to the effect of IBD.
Our study is the largest gut microbiota study in patients with
UC to date, and within it we can now begin to resolve the land-
scape of the UC gut microbiota. We were able to ﬁnd many new
associations, including the association with a decreased
Table 3 Comparison of significant taxa associations in patients with UC: family level and above




kingdom) Current study* Gevers et al† Morgan et al‡
f__Methanobacteriaceae Archea Down Not reported Not reported
f__Actinomycetaceae Actinobacteria Down Not reported Not reported
f__Coriobacteriaceae Actinobacteria Down Not reported Not reported
p__Bacteroidetes Up Not reported Not reported
o__Bacteroidales Bacteriodetes Up Not reported Not reported
f__Porphyromonadaceae Bacteriodetes Not reported Not reported Up
p__Firmicutes Down Down Not reported
f__Enterococcaceae Firmicutes Up Not reported Not reported
f__Lactobacillaceae Firmicutes Up Not reported Not reported
c__Clostridia Firmicutes Down, in lower taxonomic levels Down Not reported
o__Clostridiales Firmicutes Down, in lower taxonomic levels Down Not reported
f__Mogibacteriaceae Firmicutes Down Not reported Not reported
f__Christensenellaceae Firmicutes Down Not reported Not reported
f__Clostridiaceae Firmicutes Down, in lower taxonomic levels Down, in lower taxonomic
levels
Not reported
f__Dehalobacteriaceae Firmicutes Down Not reported Not reported
f__Lachnospiraceae Firmicutes Within the family genera, both going up and
down
Down, in lower taxonomic
levels
Not reported
f__Ruminococcaceae Firmicutes Down, in lower taxonomic levels Down Not reported
f__Veillonellaceae Firmicutes Not reported Up Not reported
f__Erysipelotrichaceae Firmicutes Down, in lower taxonomic levels Not reported Down, in lower taxonomic
levels
f__Streptococcaceae Firmicutes Not reported Not reported Down
p__Proteobacteria Up Not reported Not reported
c__Betaproteobacteria Proteobacteria Up Not reported Not reported
o__Burkholderiales Proteobacteria Up Not reported Not reported
p__Tenericutes Down Not reported Down
c__Mollicutes Tenericutes Down Not reported Down
f__Anaeroplasmataceae Tenericutes Not reported Not reported Down
f__Verrucomicrobiaceae Verrucomicrobia Down, in lower taxonomic levels Not reported Not reported
k__, kingdom; p__; phylum; c__ , class; o__ , order; f__, family.
*313 patients with IBD including 188 patients with Crohn’s disease (CD); 582 healthy controls; stool only.
†Cell Host Microbe 2014; 447 patients with CD; 221 controls; stool and biopsy.
‡Genome Biology 2012; 204 patients with IBD including 121 patients with CD and 27 controls; stool and biopsy.
§Gastroenterology 2010; 40 twin pairs concordant or discordant for CD/UC (23 CD pairs, 15 UC pairs, 2 healthy pairs).
FDR, false discovery rate.
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abundance of phylum Tenericutes, which we also ﬁnd to be
associated with more extensive UC.
Disease location is a major determinant of the gut microbial
composition in IBD
We showed the importance of disease location for the compos-
ition of the gut microbiota in patients with IBD. In our PCoA,
the gut microbiota of patients with colonic CD is more similar
to the microbiota of patients with UC than to that of patients
with ileal CD. While different clusters of gut microbiota
samples are also observed in recent IBD metagenomics research,
we have been able to relate these clusters to the disease location
phenotype.46 The importance of disease location also matches
recent insights into host genetics, in which, based on genetic
risk scores, colonic CD lies between UC and ileal CD.4 We
found that the gut microbiota composition in stool could
explain the differences in IBD disease location, while the
genetic risk variants in our cohort could not. Moreover, there is
important overlap in the clinical presentation of colonic CD and
UC, for example, the risk of developing colorectal carcinoma in
colonic CD is similar to UC, but different from ileal CD.47
Based on both the previous genetic ﬁndings and our current
microbiota ﬁndings, it is becoming more apparent that colonic
CD and ileal CD are different diseases within the IBD spectrum.
Through careful selection of healthy controls, meticulous
standardisation of stool collection, extensive phenotyping and
host genotyping, we were able to successfully perform analyses
and gain insight into the gut microbiota as the key mediator of
the IBD pathogenesis. For the ﬁrst time, we ﬁnd evidence for
the role of the gut microbiota in the onset of IBD: healthy indi-
viduals with a high genetic risk load for IBD also have unfavour-
able changes in their gut microbiota. This relationship warrants
further investigation as it might be both a potential target for
treatment and a possibility for prevention of IBD in genetically
susceptible hosts or their families.
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